Sugi Predict

Sugi Predict / Targets / PRP4K

PRP4K

Serine/threonine-protein kinase PRP4 homolog · Q13523 · PRP4K on Sugi Atlas →

18 patent compounds predicted against PRP4K, 11 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL31117871 SCHEMBL31117871 0.49 1/20
SCHEMBL6359855 SCHEMBL6359855 0.46 1/20
SCHEMBL5000553 SCHEMBL5000553 0.46 1/20
SCHEMBL27695590 SCHEMBL27695590 0.46 1/20
SCHEMBL4926122 SCHEMBL4926122 0.45 1/20
SCHEMBL27715582 SCHEMBL27715582 0.44 1/20
SCHEMBL4925658 SCHEMBL4925658 0.43 1/20
SCHEMBL28029765 SCHEMBL28029765 0.43 1/20
SCHEMBL12330453 SCHEMBL12330453 0.42 1/20
SCHEMBL5000740 SCHEMBL5000740 0.41 1/20
SCHEMBL7452995 SCHEMBL7452995 0.40 1/20

Clinical trials — most relevant to PRP4K by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa nanCOMPLETED
Study of Constitutional Platelet Disease nanUNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets nanCOMPLETED
Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes nanRECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Cellular Matrix Device for the Treatment of Mild to Moderate Knee Osteoarthritis nanUNKNOWN
Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs nanUNKNOWN
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRP4K binder may also engage these)

ProteinNameSimilarity
Q61136 — 1.000 Q61136 →
Q5RKH1 — 1.000 Q5RKH1 →
Q5R814 — 1.000 Q5R814 →
Q08DZ2 — 0.999 Q08DZ2 →
Q5XHJ5 — 0.986 Q5XHJ5 →
U2SURP U2 snRNP-associated SURP motif-containing protein 0.985 landscape →
Q3MJK5 — 0.984 Q3MJK5 →
Q09437 — 0.982 Q09437 →
E1BB50 — 0.982 E1BB50 →
Q14AX6 — 0.982 Q14AX6 →
Q9VPC0 — 0.982 Q9VPC0 →
Q5R7X2 — 0.982 Q5R7X2 →
A0A1I8M2I8 — 0.981 A0A1I8M2I8 →
Q6NV83 — 0.981 Q6NV83 →
Q9VCP0 — 0.981 Q9VCP0 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.981 landscape →
Q05512 — 0.981 Q05512 →
Q7ZYR8 — 0.981 Q7ZYR8 →
Q2QMH1 — 0.981 Q2QMH1 →
Q5VTL8 — 0.980 Q5VTL8 →
Q8C5N3 — 0.980 Q8C5N3 →
Q569Z5 — 0.980 Q569Z5 →
NSD3 Histone-lysine N-methyltransferase NSD3 0.980 landscape →
A2RTL5 — 0.980 A2RTL5 →
Q5RA93 — 0.980 Q5RA93 →
O01159 — 0.980 O01159 →
Q7L014 — 0.980 Q7L014 →
Q7XUF4 — 0.980 Q7XUF4 →
Q5PQR4 — 0.979 Q5PQR4 →
P97868 — 0.979 P97868 →